Literature DB >> 17006270

Epstein-Barr virus associated Hodgkin lymphoma in a 9-year-old girl receiving long-term methotrexate therapy for juvenile idiopathic arthritis.

Junji Takeyama1, Atsushi Sato, Kyoko Nakano, Daiki Abukawa, Ryo Ichinohazama, Masue Imaizumi.   

Abstract

We describe a case of Hodgkin lymphoma developing in a 9-year-old girl with polyarticular, rheumatoid factor-positive juvenile idiopathic arthritis treated with methotrexate (MTX), prednisone, and naproxen for 5 years. Pathologic and molecular analyses revealed that the Hodgkin cells contained Epstein-Barr virus and the viral DNA was monoclonal. She achieved complete remission after MTX withdrawal, chemotherapy, and radiation. To the best of my knowledge, this is the sixth report of Hodgkin lymphoma in patients with juvenile idiopathic arthritis receiving low dose MTX therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17006270     DOI: 10.1097/01.mph.0000212960.66221.e7

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  4 in total

1.  Spontaneous regression of Epstein-Barr virus-associated lymphoproliferative disorder in a juvenile idiopathic arthritis patient after the discontinuation of methotrexate and etanercept.

Authors:  Ariane Klein; Harald Reinhard; Annette M Mueller; Gerd Horneff
Journal:  Eur J Rheumatol       Date:  2017-02-23

Review 2.  Diagnosis and management of infectious complications of childhood rheumatic diseases.

Authors:  Rhina D Castillo; Wendy De la Pena; Katherine A B Marzan
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.592

Review 3.  Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances.

Authors:  Apostolos Kontzias; Petros Efthimiou
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 4.  Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis.

Authors:  Alex R Kemper; Heather A Van Mater; Remy R Coeytaux; John W Williams; Gillian D Sanders
Journal:  BMC Pediatr       Date:  2012-03-15       Impact factor: 2.125

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.